← Media

RLS treatment changed for a reason. Many patients did well early on dopamine agonists, then developed harder-to-control symptoms over time.

Augmentation

With chronic dopamine agonist use, some people develop augmentation: symptoms start earlier, spread, intensify, and demand higher doses. That cycle can turn manageable RLS into all-day distress.

Other risks

• Impulse-control behaviors. Gambling, compulsive shopping, or hypersexual behavior can emerge in susceptible patients.
• Sleep attacks or severe drowsiness. Including potentially dangerous episodes around driving.

What we use instead

Current first-line options are usually alpha-2-delta ligands (gabapentin, pregabalin, gabapentin enacarbil), which have lower augmentation risk. Iron status also matters. If iron stores are low, iron repletion is often part of first-line management.

If you are on a dopamine agonist, do not stop abruptly. Work with your clinician on a gradual transition plan to reduce rebound symptoms and withdrawal problems.

Bottom line

For many patients, the safer long-term strategy is iron optimization plus alpha-2-delta therapy, not chronic dopamine agonist escalation. If your RLS pattern is worsening earlier in the day, ask about augmentation.

See the RLS Foundation and NINDS fact sheet for more. Garcia-Borreguero D et al. Sleep Med. 2016;21:1-11.

Educational content only; this is not personalized medical advice. If you have urgent symptoms, seek emergency care.